Reviva Pharmaceuticals Holdings, Inc. (RVPH)
 NASDAQ: RVPH · Real-Time Price · USD
 0.5880
 -0.0163 (-2.70%)
  Oct 31, 2025, 1:19 PM EDT - Market open
RVPH Stock Forecast
Stock Price Forecast
The 6 analysts that cover RVPH stock have a consensus rating of "Strong Buy" and an average price target of $3.33, which forecasts a 466.33% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $7.00.
Price Target: $3.33 (+466.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RVPH stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | 
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 | 
| Buy | 1 | 1 | 1 | 1 | 1 | 1 | 
| Hold | 0 | 0 | 0 | 0 | 0 | 0 | 
| Sell | 0 | 0 | 0 | 0 | 0 | 0 | 
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 | 
| Total | 5 | 5 | 5 | 5 | 6 | 6 | 
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date | 
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +240.14% | Oct 28, 2025 | 
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $4 | Strong Buy | Maintains | $11 → $4 | +580.27% | Oct 27, 2025 | 
| Chardan Capital | Chardan Capital | Strong Buy Initiates $2 | Strong Buy | Initiates | $2 | +240.14% | Sep 29, 2025 | 
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +240.14% | Sep 19, 2025 | 
| Benchmark | Benchmark | Buy Maintains $14 → $7 | Buy | Maintains | $14 → $7 | +1,090.48% | Sep 15, 2025 | 
Financial Forecast
Revenue This Year
 n/a 
 Revenue Next Year
 3.40M 
 EPS This Year
 -0.46 
 from -0.90
EPS Next Year
 -0.37 
 from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | n/a | 21.0M | |||
| Avg | n/a | 3.4M | |||
| Low | n/a | n/a | 
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - | 
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | -0.38 | - | |||
| Avg | -0.46 | -0.37 | |||
| Low | -0.51 | -0.83 | 
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - | 
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.